Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score-Reference-Cited by-同舟云学术

Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score

Published:2014-03-19 Issue:10 Volume:55 Page:2277-2283
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Zaroulis Chrysothea K.,Chairopoulos Konstantinos,Sachanas Sotirios P.,Maltezas Dimitris,Tzenou Tatiana,Pessach Ilias,Koulieris Efstathios,Koutra Eleni,Kilindireas Konstantinos,Pangalis Gerasimos A.,Kyrtsonis Marie-Christine

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.873535

Reference49 articles.

2. Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers

3. Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment

4. Nuclear factor-KappaB modulation as a therapeutic approach in hematologic malignancies

5. Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model;Cancers;2024-07-18

2. Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence;Journal of Neurology, Neurosurgery & Psychiatry;2023-04-04

3. Vincristine- and bortezomib-induced neuropathies – from bedside to bench and back;Experimental Neurology;2021-02

4. Sexually dimorphic therapeutic response in bortezomib-induced neuropathic pain reveals altered pain physiology in female rodents;Pain;2019-09-03

5. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction;Clinical Lymphoma Myeloma and Leukemia;2017-08